Newsletter

The Hemophilia Foundation of Oregon enhances the quality of life for individuals with bleeding disorders and their families through advocacy, assistance, outreach, education and research support.

RSS RSS Newsfeed

  • FDA Approves Once-Weekly Subcutaneous Therapy for Hemophilia A Patients with Inhibitors November 16, 2017
    The U.S. Food and Drug Administration (FDA) has approved HEMLIBRA® (emicizumab) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with factor VIII inhibitors. Read more about FDA Approves Once-Weekly Subcutaneous Therapy for Hemophilia A Patients with Inhibitors
  • Call to Action on Senate Tax Plan November 16, 2017
    Call your Senators now and share how the tax reform proposal will harm the bleeding disorders community. Read more about Call to Action on Senate Tax Plan

Bioverativ

Bioverativ